The company’s initial areas of product focus are two-fold. 

First, the company is planning to maximize the considerable commercial opportunity offered by its robust portfolio of issued patents by seeking a pharmaceutical partner(s) to which Prismic will sub-license the rights to formulate, develop and market prescription products for the treatment of CNS disorders. 

Second, the company will internally formulate, develop, and market products, based on the referenced patents, which conform to the requirements of the Orphan Drug Act’s Medical Food classification, and which are indicated for the dietary management of the metabolic processes associated with defined disorders of the central nervous system.